Omega Healthcare Invts Azioni (NYSE: OHI)

Ultime notizie per Omega Healthcare Invts (NYSE:OHI) Azioni

Omega Healthcare Invts

Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Its core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (SNFs), assisted living facilities (ALFs), and to a lesser extent, independent living facilities (ILFs), rehabilitation and acute care facilities (specialty facilities) and medical office buildings (MOBs).

Real Estate

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Incertezza sui mercati? I dividendi nel settore immobiliare possono offrire stabilità e guadagni. Le azioni da monitorare.

Titoli a dividendi: 3 azioni immobiliari ad alto rendimento da tenere d&#39;occhio

Earnings

Come proteggere i tuoi investimenti in periodi di incertezza? Focus sui titoli del settore immobiliare che offrono rendite elevate.

3 titoli con dividendi oltre il 6% per un portafoglio anti-crisi

$LTC

Gli analisti mettono in evidenza 3 titoli che offrono rendimenti elevati sui dividendi, ideali per investitori in cerca di reddito costante.

3 azioni immobiliari con rendimenti alti consigliate da Wall Street

Omega Healthcare Investors, Inc. Common Stock

Omega Healthcare Investors Inc

OHIO ART CO by Ohio Art Company (The)

Ohio Valley Banc Corporation

<p>Omega Healthcare Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) is a real estate investment trust providing financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities located in the U.S. and the U.K.</p>
<p>It is set to report its Q1 2025 earnings on May 1. Wall Street analysts expect the company to post EPS of $0.75, up from $0.68 in the year-ago period. According to Benzinga Pro, quarterly revenue is expected to reach $276.66 million, up from $243.30 million a year earlier.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>You can invest today for just $0.26/share with a $1000 minimum.</strong></a></strong></li>
<li><strong><a href="https://www.benzinga.com/money/arrived-centennial">Jeff Bezos-Backed Arrived Homes Hits A Big Sale On Charlotte Property – Investors Earning A 34.7% Return</a></strong></li>
</ul>
<h2 class="wp-block-heading">If You Bought Omega Healthcare Stock 10 Years Ago</h2>
<p>The company's stock traded at approximately $40.41 per share 10 years ago. If you had invested $10,000, you could have bought roughly 247 shares. Currently, shares trade at $38, meaning your investment's value could have declined to $9,404 from stock price depreciation. However, Omega Healthcare also paid dividends during these 10 years.&nbsp;</p>
<p>Omega Healthcare's dividend yield is currently 7.05%. Over the last 10 years, it has paid about $24.11 in dividends per share, which means you could have made $5,966 from dividends alone.&nbsp;</p>
<p>Summing up $9,404 and $5,966, we end up with the final value of your investment, which is $15,370. This is how much you could have made if you had invested $10,000 in Omega Healthcare stock 10 years ago. This means a total return of 53.7%. However, this figure is significantly less than the S&amp;P 500 total return for the same period, which was 235%.</p>
<p><strong>Trending: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"><strong> </strong><strong>here&#8217;s a breakdown on what&#8217;s behind this formula.</strong></a></strong></p>
<h2 class="wp-block-heading">What Could The Next 10 Years Bring?&nbsp;</h2>
<p>Omega Healthcare has a consensus rating of "Buy" and a price target of $36.11 based on the ratings of 21 analysts. The price target implies a nearly 5% potential downside from the current stock price.</p>
<p>On Feb. 5, the company announced its Q4 2024 earnings, posting FFO of $0.74, compared to the consensus estimate of $0.73, and revenues of $279.318 million, compared to the consensus of $275.668 million, as reported by <a href="https://www.benzinga.com/news/earnings/25/02/43510274/omega-healthcare-invts-q4-2024-ffo-0-74-beats-0-73-estimate-sales-279-318m-beat-275-668m-estimate">Benzinga</a>.</p>
<p>"The backdrop continues to be favorable. Operating metrics remain strong, with both occupancy and coverage modestly improving in the quarter. The pipeline remains very active, and we have a cost of capital that should allow us to continue to accretively invest," CEO Taylor Pickett said.</p>
<p><strong><em>See Also: Dogecoin millionaires are increasing –<a href="https://www.benzinga.com/money/dogecoin-millionaires"><strong><em> </em></strong><strong><em>investors with $1M+ in DOGE revealed!</em></strong></a></em></strong></p>
<p>The company provided its full-year 2025 guidance, expecting adjusted FFO to be between $2.90 and $2.98 per diluted share.</p>
<p>Given the expected downside potential, growth-focused investors may not find Omega Healthcare stock attractive. Conversely, the stock can be a good option for income-focused investors, who can benefit from the company's solid dividend yield of 7.05%.</p>
<p>Check out this <a href="https://www.benzinga.com/personal-finance/25/03/44450148/why-pepsico-restaurant-brands-and-fifth-third-bancorp-are-winners-for-passive-income">article by Benzinga</a> for three more stocks offering high dividend yields.&nbsp;</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></strong></li>
<li><strong>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>with $1,000 you can invest at just $0.26/share!</strong></a></strong></li>
</ul>


Personal Finance

If You Invested $10K In Omega Healthcare Stock 10 Years Ago, How Much Would You Have Now?

<p>During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.</p>
<p>Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.</p>
<p>Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.</p>
<h3 class="wp-block-heading"><strong>Healthcare Realty Trust Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 7.40%</li>
<li><strong>Wedbush </strong>analyst Richard Anderson downgraded the stock from Neutral to Underperform and slashed the price target from $18 to $16 on Jan. 2, 2025. This analyst has an accuracy rate of 64%.</li>
<li><strong>Wells Fargo </strong>analyst James Feldman assumed an Underweight rating and increased the price target from $16 to $17 on Oct. 1, 2024. This analyst has an accuracy rate of 61%.</li>
<li><strong>Recent News:</strong> On Feb. 19, Healthcare Realty Trust reported quarterly earnings of 40 cents per share.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0328">latest HR news</a>.</li>
</ul>
<h3 class="wp-block-heading"><strong>Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 7.15%</li>
<li><strong>Wells Fargo </strong>analyst Connor Siversky downgraded the stock from Overweight to Equal-Weight and lowered the price target from $41 to $39 on March 27, 2025. This analyst has an accuracy rate of 67%.</li>
<li><strong>Truist Securities </strong>analyst Michael Lewis maintained a Hold rating and increased the price target from $38 to $39 on March 18, 2025. This analyst has an accuracy rate of 70%</li>
<li><strong>Recent News:</strong> On Feb. 5, the company posted upbeat quarterly sales.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0328">OHI news</a></li>
</ul>
<h3 class="wp-block-heading"><strong>OUTFRONT Media Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUT#NYSE">OUT</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield: </strong>7.32%</li>
<li><strong>Morgan Stanley </strong>analyst Benjamin Swinburne maintained an Equal-Weight rating and increased the price target from $17.51 to $18.54 on Dec. 18, 2024. This analyst has an accuracy rate of 75%.</li>
<li><strong>TD Cowen </strong>analyst Lance Vitanza initiated coverage on the stock with a Hold rating and a price target of $16.48 on July 16, 2024. This analyst has an accuracy rate of 74%.</li>
<li><strong>Recent News: </strong>On Feb. 25, Outfront Media reported fourth-quarter financial results and beat its EPS and revenue estimates.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0328">latest OUT news</a> </li>
</ul>
<p><figure class="wp-block-embed"><br />
<div class="wp-block-embed__wrapper">
<a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock" title="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock">https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock</a>
</div>
<p></p></figure></p>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock">Jim Cramer: Stryker Is A &#8216;Good&#8217; Company, Says He Likes This Utilities Stock</a></strong></li>
</ul>


Wall Street's Most Accurate Analysts Spotlight On 3 Real Estate Stocks With Over 7% Dividend Yields

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Jefferies analyst Blayne Curtis downgraded the rating for <strong>Advanced Micro Devices, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) from Buy to Hold and lowered the price target from $135 to $120. Advanced Micro Devices shares closed at $110.19 on Wednesday. <a href="https://www.benzinga.com/quote/amd/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Ryan Brinkman downgraded <strong>OPENLANE, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAR#NYSE">KAR</a>) from Overweight to Neutral and lowered the price target from $23 to $20. Openlane shares closed at $20.99 on Wednesday. <a href="https://www.benzinga.com/quote/KAR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Rajat Gupta downgraded the rating for <strong>TrueCar, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUE#NASDAQ">TRUE</a>) from Neutral to Underweight. TrueCar shares closed at $1.79 on Wednesday. <a href="https://www.benzinga.com/quote/TRUE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Rajat Gupta downgraded <strong>CarGurus, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) from Overweight to Neutral and cut the price target from $42 to $34. CarGurus shares closed at $31.33 on Wednesday. <a href="https://www.benzinga.com/quote/CARG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Connor Siversky downgraded <strong>Omega Healthcare Investors, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) from Overweight to Equal-Weight and lowered the price target from $41 to $39. Omega Healthcare shares closed at $37.72 on Wednesday.  <a href="https://www.benzinga.com/quote/OHI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<p>Considering buying AMD stock? Here&#8217;s what analysts think: </p>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/03/44496478/top-2-industrials-stocks-that-may-crash-in-q1">Top 2 Industrials Stocks That May Crash In Q1</a></strong></li>
</ul>


Downgrades

CARG

TRUE

This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

<p>Wells Fargo  analyst Connor Siversky   downgrades Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) from Overweight to Equal-Weight and lowers the price target from $41 to $39.</p>


Wells Fargo Downgrades Omega Healthcare Invts to Equal-Weight, Lowers Price Target to $39

<p>Truist Securities  analyst Michael Lewis   maintains Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) with a Hold and raises the price target from $38 to $39.</p>


Truist Securities Maintains Hold on Omega Healthcare Invts, Raises Price Target to $39

WIIM

LAMR

Shares of real estate ETFs are trading lower following a rise in treasury yields, which can raise borrowing costs for firms and enhance the relative attractiveness of bonds for income-oriented investors.

<p>Wells Fargo  analyst John Kilichowski   maintains Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) with a Overweight and lowers the price target from $43 to $41.</p>


Wells Fargo Maintains Overweight on Omega Healthcare Invts, Lowers Price Target to $41

CBRE

EQIX

WELL

WHLR

Shares of REIT and utility stocks are trading lower amid overall market weakness. Rising Treasury yields may be driving a rotation out of income-paying sectors.

<p>During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.</p>
<p>Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.</p>
<p>Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.</p>
<h3 class="wp-block-heading"><strong>Healthcare Realty Trust Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 7.33%</li>
<li><strong>Wedbush </strong>analyst Richard Anderson downgraded the stock from Neutral to Underperform and cut the price target from $18 to $16 on Jan. 2, 2025. This analyst has an accuracy rate of 65%.</li>
<li><strong>Wells Fargo </strong>analyst James Feldman assumed an Underweight rating and increased the price target from $16 to $17 on Oct. 1, 2024. This analyst has an accuracy rate of 60%.</li>
<li><strong>Recent News:</strong> On Feb. 19, Healthcare Realty Trust reported quarterly earnings of 40 cents per share.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1">HR news</a>. </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="897" height="397" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142718/image-208.png" alt="" class="wp-image-798244" style="width:517px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142718/image-208.png 897w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142718/image-208-300x133.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142718/image-208-768x340.png 768w" sizes="(max-width: 897px) 100vw, 897px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 7.27%</li>
<li><strong>JMP Securities </strong>analyst Aaron Hecht reiterated a Market Perform rating on Feb. 7, 2025. This analyst has an accuracy rate of 60%.</li>
<li><strong>RBC Capital </strong>analyst Michael Carroll maintained a Sector Perform rating and raised the price target from $39 to $43 on Nov. 11, 2024. This analyst has an accuracy rate of 63%.</li>
<li><strong>Recent News:</strong> On Feb. 5, the company posted upbeat quarterly sales.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1">OHI news</a>.  </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="806" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25143021/image-211.png" alt="" class="wp-image-798252" style="width:634px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25143021/image-211.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25143021/image-211-300x266.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25143021/image-211-768x682.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>EPR Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield: </strong>6.75%</li>
<li><strong>JP Morgan </strong>analyst Anthony Paolone maintained an Overweight rating and increased the price target from $48 to $51 on Sept. 9, 2024. This analyst has an accuracy rate of 64%.</li>
<li><strong>Truist Securities </strong>analyst Ki Bin Kim maintained a Hold rating and boosted the price target from $44 to $46 on Aug. 16, 2024. This analyst has an accuracy rate of 69%.</li>
<li><strong>Recent News: </strong>On Jan. 27, EPR Properties elected John Peter (JP) Suarez to its Board of Trustees.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1">latest EPR news</a> </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="807" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142824/image-210.png" alt="" class="wp-image-798248" style="width:506px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142824/image-210.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142824/image-210-300x267.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142824/image-210-768x683.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure></p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/02/43937701/how-to-earn-500-a-month-from-lowes-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Lowe&#8217;s Stock Ahead Of Q4 Earnings</a></strong></li>
</ul>


Wall Street's Most Accurate Analysts Spotlight On 3 Real Estate Stocks With Over 6% Dividend Yields

<p>JMP Securities  analyst Aaron Hecht   reiterates Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) from Market Perform to Market Perform.</p>


Reiteration

JMP Securities Reiterates Market Perform on Omega Healthcare Invtsto Market Perform

<p>The earnings results for <strong>Omega Healthcare Invts</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) for Q4 were made public on Wednesday, February 5, 2025 at 04:15 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Omega Healthcare Invts beat estimated earnings by 1.0%, reporting an EPS of $0.74 versus an estimate of $0.73.</p>
<p>Revenue was up $40.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous quarter, the company beat on EPS by $0.03, resulting in a 0.0% increase change in the share price the following day.</p>
<p>Here's a look at Omega Healthcare Invts's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.71</td>
<td>0.68</td>
<td>0.65</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.74</td>
<td>0.71</td>
<td>0.68</td>
<td>0.68</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>261.64M</td>
<td>246.73M</td>
<td>231.64M</td>
<td>233.82M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>276.03M</td>
<td>252.75M</td>
<td>243.30M</td>
<td>239.32M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Omega Healthcare Invts management provided guidance for FY 2025, expecting earnings between $2.9 and $2.98 per share.</p>
<p>To track all earnings releases for Omega Healthcare Invts <a href="https://www.benzinga.com/quote/OHI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Omega Healthcare Invts Q4 Earnings Assessment

<p><strong>Omega Healthcare Invts</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) reported its Q4 earnings results on Wednesday, February 5, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Omega Healthcare Invts beat estimated earnings by 1.0%, reporting an EPS of $0.74 versus an estimate of $0.73.</p>
<p>Revenue was up $40.00 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company beat on EPS by $0.03 in the previous quarter, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at Omega Healthcare Invts's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.71</td>
<td>0.68</td>
<td>0.65</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.74</td>
<td>0.71</td>
<td>0.68</td>
<td>0.68</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>261.64M</td>
<td>246.73M</td>
<td>231.64M</td>
<td>233.82M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>276.03M</td>
<td>252.75M</td>
<td>243.30M</td>
<td>239.32M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Omega Healthcare Invts management provided guidance for FY 2025, expecting earnings between $2.9 and $2.98 per share.</p>
<p>To track all earnings releases for Omega Healthcare Invts <a href="https://www.benzinga.com/quote/OHI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Breakdown: Omega Healthcare Invts Q4

<p>The Q4 earnings report for <strong>Omega Healthcare Invts</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) was released on Wednesday, February 5, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Omega Healthcare Invts beat estimated earnings by 1.0%, reporting an EPS of $0.74 versus an estimate of $0.73.</p>
<p>Revenue was up $40.00 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>During the previous quarter, the company beat on EPS by $0.03, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at Omega Healthcare Invts's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.71</td>
<td>0.68</td>
<td>0.65</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.74</td>
<td>0.71</td>
<td>0.68</td>
<td>0.68</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>261.64M</td>
<td>246.73M</td>
<td>231.64M</td>
<td>233.82M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>276.03M</td>
<td>252.75M</td>
<td>243.30M</td>
<td>239.32M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Omega Healthcare Invts management provided guidance for FY 2025, expecting earnings between $2.9 and $2.98 per share.</p>
<p>To track all earnings releases for Omega Healthcare Invts <a href="https://www.benzinga.com/quote/OHI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Omega Healthcare Invts: Q4 Earnings Insights

<p><strong>Omega Healthcare Invts</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) reported its Q4 earnings results on Wednesday, February 5, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Omega Healthcare Invts beat estimated earnings by 1.0%, reporting an EPS of $0.74 versus an estimate of $0.73.</p>
<p>Revenue was up $40.00 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>During the previous quarter, the company beat on EPS by $0.03, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at Omega Healthcare Invts's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.71</td>
<td>0.68</td>
<td>0.65</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.74</td>
<td>0.71</td>
<td>0.68</td>
<td>0.68</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>261.64M</td>
<td>246.73M</td>
<td>231.64M</td>
<td>233.82M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>276.03M</td>
<td>252.75M</td>
<td>243.30M</td>
<td>239.32M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Omega Healthcare Invts management provided guidance for FY 2025, expecting earnings between $2.9 and $2.98 per share.</p>
<p>To track all earnings releases for Omega Healthcare Invts <a href="https://www.benzinga.com/quote/OHI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Summary: Omega Healthcare Invts Q4

<p>The earnings results for <strong>Omega Healthcare Invts</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) for Q4 were made public on Wednesday, February 5, 2025 at 04:15 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Omega Healthcare Invts beat estimated earnings by 1.0%, reporting an EPS of $0.74 versus an estimate of $0.73.</p>
<p>Revenue was up $40.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>During the previous quarter, the company beat on EPS by $0.03, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at Omega Healthcare Invts's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.71</td>
<td>0.68</td>
<td>0.65</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.74</td>
<td>0.71</td>
<td>0.68</td>
<td>0.68</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>261.64M</td>
<td>246.73M</td>
<td>231.64M</td>
<td>233.82M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>276.03M</td>
<td>252.75M</td>
<td>243.30M</td>
<td>239.32M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Omega Healthcare Invts management provided guidance for FY 2025, expecting earnings between $2.9 and $2.98 per share.</p>
<p>To track all earnings releases for Omega Healthcare Invts <a href="https://www.benzinga.com/quote/OHI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Omega Healthcare Invts Q4 Earnings Report: What Investors Need to Know

Guidance

Omega Healthcare Investors Sees FY25 Adj. FFO $2.90-$2.98 Vs $2.99 Est.

<p>The Q4 earnings report for <strong>Omega Healthcare Invts</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) was released on Wednesday, February 5, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Omega Healthcare Invts beat estimated earnings by 1.0%, reporting an EPS of $0.74 versus an estimate of $0.73.</p>
<p>Revenue was up $40.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>The company beat on EPS by $0.03 in the last quarter, resulting in a 0.0% increase share price change the following day.</p>
<p>Here's a look at Omega Healthcare Invts's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.71</td>
<td>0.68</td>
<td>0.65</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.74</td>
<td>0.71</td>
<td>0.68</td>
<td>0.68</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>261.64M</td>
<td>246.73M</td>
<td>231.64M</td>
<td>233.82M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>276.03M</td>
<td>252.75M</td>
<td>243.30M</td>
<td>239.32M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Omega Healthcare Invts management provided guidance for FY 2025, expecting earnings between $2.9 and $2.98 per share.</p>
<p>To track all earnings releases for Omega Healthcare Invts <a href="https://www.benzinga.com/quote/OHI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Omega Healthcare Invts Earnings Review: Q4 Summary

<p>Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.73 by 1.37 percent. This is a 8.82 percent increase over earnings of $0.68 per share from the same period last year.  The company reported quarterly sales of $279.318 million which beat the analyst consensus estimate of $275.668 million by 1.32 percent.  This is a 16.71 percent increase over sales of $239.319 million the same period last year.</p>


Earnings Beats

Omega Healthcare Invts Q4 2024 FFO $0.74 Beats $0.73 Estimate, Sales $279.318M Beat $275.668M Estimate

ALGN

AMSC

AOSL

APPS

ARAY

ARCC

ARES

ASGN

ASYS

AZTA

BARK

BLBD

BSBR

CENT

CENTA

CMRE

CNMD

CNXN

COHR

CPAY

CPRI

CRTO

CSGS

CTSH

CTVA

DGII

DLHC

ENSG

EQNR

EZPW

FORM

GEOS

HOLX

ITUB

KMPR

LFVN

LSAK

LUCK

LVWR

MSTR

MTRX

MUSA

NOTV

NTGR

NVST

NWSA

ODFL

ORLY

PAHC

PFGC

Earnings Scheduled For February 5, 2025

<p>During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.</p>
<p>Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.</p>
<p>Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.</p>
<h3 class="wp-block-heading"><strong>Medical Properties Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 8.54%</li>
<li><strong>Truist Securities </strong>analyst Michael Lewis maintained a Hold rating and cut the price target from $6 to $4 on Dec. 19, 2024. This analyst has an accuracy rate of 69%.</li>
<li><strong>RBC Capital </strong>analyst Michael Carroll downgraded the stock from Outperform to Sector Perform with a price target of $5 on May 14, 2024. This analyst has an accuracy rate of 61%.</li>
<li><strong>Recent News:</strong> On Nov.7, Medical Properties Trust reported worse-than-expected third-quarter financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1">latest MPW news.</a> </li>
</ul>
<p><figure class="wp-block-image is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/8356f98b-748a-4a66-8e7b-6e4f0dc6db31" alt="" style="width:606px;height:auto" /></a></figure></p>
<h3 class="wp-block-heading"><strong>EPR Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 7.74%</li>
<li><strong>JP Morgan </strong>analyst Anthony Paolone maintained an Overweight rating and raised the price target from $48 to $51 on Sept. 9, 2024. This analyst has an accuracy rate of 64%.</li>
<li><strong>Truist Securities </strong>analyst Ki Bin Kim maintained a Hold rating and boosted the price target from $44 to $46 on Aug. 16, 2024. This analyst has an accuracy rate of 67%.</li>
<li><strong>Recent News:</strong> On Oct. 30, EPR Props posted better-than-expected quarterly results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1">latest EPR new</a>s.</li>
</ul>
<p><figure class="wp-block-image is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/25fde8ab-3a45-4b71-980a-0efe0c0d9950" alt="" style="width:631px;height:auto" /></a></figure></p>
<h3 class="wp-block-heading"><strong>Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield: </strong>7.39%</li>
<li><strong>RBC Capital </strong>analyst Michael Carroll maintained a Sector Perform rating and raised the price target from $39 to $43 on Nov. 11, 2024. This analyst has an accuracy rate of 61%.</li>
<li><strong>Wells Fargo </strong>analyst Connor Siversky assumed an Overweight rating and increased the price target from $40 to $43 on Oct. 1, 2024. This analyst has an accuracy rate of 63%.</li>
<li><strong>Recent News: </strong>On Jan. 6, Omega Healthcare Investors named Matthew Gourmand as President.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1">OHI news</a>.</li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="893" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10133010/image-64.png" alt="" class="wp-image-728777" style="width:563px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10133010/image-64.png 893w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10133010/image-64-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10133010/image-64-768x711.png 768w" sizes="(max-width: 893px) 100vw, 893px" /></a></figure></p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/01/42917071/top-2-health-care-stocks-that-are-ticking-portfolio-bombs-2">Top 2 Health Care Stocks That Are Ticking Portfolio Bombs</a></strong></li>
</ul>


Wall Street's Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 7% Dividend Yields

Press Releases

Omega Reports Third Quarter 2024 Results and Recent Developments

Omega Announces Key Leadership Changes

Omega Announces Fourth Quarter Earnings Release Date and Conference Call

Omega Announces Quarterly Dividend

Omega Reports Fourth Quarter and Full Year 2024 Results

Inspīr Embassy Row Celebrates Grand Opening, Ushering in New Era of Luxury Senior Living in Washington D.C.

All 15 Maplewood Senior Living Communities and Inspῑr Carnegie Hill Receive Reputation.com's Esteemed Awards

Ortelius Nominates Six Highly Qualified and Independent Candidates for Election to the Board of Brookdale Senior Living Inc.

Comments

Omega Healthcare Invts

Notizie

Ultime notizie per Omega Healthcare Invts (NYSE:OHI) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO